Analytical Data
-
基因名
HVEM/TNFRSF14
-
简介
HVEM (herpes virus entry mediator, TNFRSF14, CD270) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). HVEM is a bidirectional molecular switch that transduces positive and negative signals. HVEM can deliver proinflammatory and survival signals when engaged by BTLA or LIGHT, stimulating lymphocyte proliferation, activation, and inducing inflammatory reactions. While, HVEM binds to CD160 and BTLA, inhibiting T- and B-lymphocyte activation and proliferation[2][3]. HVEM/TNFRSF14 Protein, Mouse (HEK293, Fc) is a recombinant protein with a C-Terminal Fc label, It consists of 169 amino acids (Q39-V207) and is produced in HEK293 cells.
- Application
-
生物活性
1. The ED50 as determined by its ability to bind Human BTLA in functional ELISA is typically 1.17 μg/mL. 2. Measured by its ability to inhibit TNF-beta -mediated cytotoxicity using L-929 mouse fibroblast cells. The ED50 this effect is 1.688 μg/mL in the presence of 50 pg/mL of Recombinant Human TNF-beta, corresponding to a specific activity is 5.92×102 units/mg. Measured by its ability to inhibit TNF-beta -mediated cytotoxicity using L-929 mouse fibroblast cells. The ED50 for this effect is 1.688 μg/mL in the presence of 50 pg/mL of Recombinant Human TNF-beta, corresponding to a specific activity is 5.92×102 units/mg.
-
别名
Tnfrsf14; hvem; Tumor necrosis factor receptor superfamily member 14; Herpes virus entry mediator A; Herpesvirus entry mediator A; HveA; Tumor necrosis factor receptor-like 2; TR2; CD antigen CD270
-
种属
Mouse
-
表达系统
HEK293
-
标签
C-hFc
-
纯度
Greater than 95% as determined by reducing SDS-PAGE.
-
蛋白编号
Q80WM9
-
表达区间
Q39-V207
-
蛋白长度
Partial
-
分子量
50-65 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HVEM, also known as TNFRSF14 (Tumor Necrosis Factor Receptor Superfamily Member 14), is a critical member of the TNF receptor family that plays a significant role in regulating immune responses. It is primarily expressed in lymphocytes and serves as a receptor for several ligands, including LIGHT, BTLA, and lymphotoxin. The interaction between HVEM and its ligands is essential for modulating T-cell activation, proliferation, and apoptosis. Dysregulation of HVEM signaling has been implicated in various autoimmune diseases, cancers, and infections, highlighting its potential as a therapeutic target. Research on HVEM/TNFRSF14 recombinant proteins focuses on elucidating their structural and functional properties, which are crucial for understanding the mechanisms of immune modulation. This research often involves the production and characterization of recombinant HVEM proteins to explore their interactions with ligands and downstream signaling pathways, as well as their potential applications in disease treatment and vaccine development. By advancing our knowledge of HVEM biology, we can potentially discover novel strategies for enhancing immune responses or suppressing unwanted inflammation, thus paving the way for innovative therapies in oncology and immunology.
